Septerna Inc/$SEPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Septerna Inc
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Ticker
$SEPN
Sector
Primary listing
Employees
75
Headquarters
Website
Septerna Inc Metrics
BasicAdvanced
$927M
-
-$2.84
-
-
Price and volume
Market cap
$927M
52-week high
$21.81
52-week low
$4.66
Average daily volume
275K
Financial strength
Current ratio
22.089
Quick ratio
21.758
Long term debt to equity
5.971
Total debt to equity
6.508
Profitability
EBITDA (TTM)
-100.602
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-12,053.03%
Operating margin (TTM)
-14,071.07%
Effective tax rate (TTM)
0.34%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-21.58%
Return on equity (TTM)
-32.78%
Valuation
Price to revenue (TTM)
881.73
Price to book
2.46
Price to tangible book (TTM)
2.46
Price to free cash flow (TTM)
-7.709
Free cash flow yield (TTM)
-12.97%
Free cash flow per share (TTM)
-2.698
Growth
Revenue change (TTM)
-13.37%
Earnings per share change (TTM)
-39.73%
Bulls say / Bears say
Septerna's exclusive collaboration with Novo Nordisk could be worth up to $2.2 billion, including over $200 million in upfront and near-term payments, underscoring the strength of Septerna's GPCR platform and lowering risk in its metabolic pipeline (Reuters).
Shares of SEPN surged nearly 45% on the day the Novo Nordisk partnership was announced, indicating strong market confidence in Septerna's potential to co-develop oral therapies for obesity and cardiometabolic diseases (MarketWatch).
Septerna holds the option to enter into a global profit-sharing deal for one partnered program, instead of receiving future milestone and royalty payments, which may lead to higher long-term gains if those products reach commercialization (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Septerna Inc stock?
Septerna Inc (SEPN) has a market cap of $927M as of October 07, 2025.
What is the P/E ratio for Septerna Inc stock?
The price to earnings (P/E) ratio for Septerna Inc (SEPN) stock is 0 as of October 07, 2025.
Does Septerna Inc stock pay dividends?
No, Septerna Inc (SEPN) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next Septerna Inc dividend payment date?
Septerna Inc (SEPN) stock does not pay dividends to its shareholders.
What is the beta indicator for Septerna Inc?
Septerna Inc (SEPN) does not currently have a Beta indicator.